Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.
Amid Favorable Results, Questions About Syfovre’s Safety | ASRS 2023
The manufacturer has reported seven causes of retinal vasculitis associated with Syfovre. Results of an open-label, extension study presented at the American Society of Retina Specialists meeting today show favorable results among those who crossed over from sham to active treatment.
When a Biosimilar Might Increase Not Decrease Costs | Ravi Parikh, M.D., M.P.H., ASRS 2023
The approval of an ophthalmic bevacizumab biosimilar might mean the end of low-cost, repackaged Avastin as an anti-VEGF treatment for retinal diseases, with the unintended consequence of adding $457 million to Medicare B spending.
The Anti-VEGF Biosimilars Paradox | Ravi Parikh, M.D., M.P.H., ASRS 2023
In an interview with MHE, Parikh, a retina specialist in New York and director of healthcare delivery research for the Department of Ophthalmology at NYU Grossman School of Medicine, described the current situation of biosimilars in retinal medicine and the attitudes of retinal specialists about using the lower-cost alternatives.
Endophthalmitis After Anti-VEGF Injections: A Rare But Real Risk | ASRS 2023
Researchers used the American Academy of Ophthalmology's IRIS database to quantify the risk of endophthalmitis — inflammation of intraocular fluids — after injections with anti-VEGF drugs. They found that post-injection endophthalmitis occurs, on average, once every 3,500 injections.
Eylea Biosimilar Produces Favorable Results in a Switching Study | ASRS 2023
Samsung Bioepsis' SB15 was comparable to Eylea (aflibercept) in a 56-week randomized clinical trial that included a rerandomization at 32 weeks. The rerandomization resulted in 111 study volunteers switching from Eylea to the biosimilar for the last part of the study.
The Long and Short (Interval Switch) of the PULSAR Trial | ASRS 2023
About 20% of patients in the trial of a high-dose, longer-interval regimen of Eylea (aflibercept )switched to shorter intervals, according to data presented today at the American Society of Retinal Specialists annual scientific meeting, which is being held in Seattle. Researchers didn't find any clues as to why in their baseline characteristics.
Cost-effectiveness of Eylea Monotherapy vs. Bevacizumab-first Strategy for Treating Diabetic Macular Edema | ASRS 2023
Research shows a $12,575 savings over two years and no difference in outcome, which result in an incremental cost-effectiveness ratio (ICER) of $873,000.
Subgroup Analysis of PULSAR Produces No Surprises | Keyvan Koushan, M.D., ASRS 2023
A post-hoc analysis didn’t reveal any differences in outcomes by race, macular thickness or baseline visual acuity.
A Primer on PULSAR | Keyvan Koushan, M.D., ASRS 2023
In an interview with Managed Healthcare Executive prior to the meeting, Keyvan Koushan, M.D., a retina specialist at the Toronto Retina Institute and a lecturer in the Department of Ophthalmology and Vision Sciences at the University of Toronto, briefly described the design of the PULSAR trial and the positive results that have been reported so far.
Vision Loss From Silicone Oil Tamponade: Possible Explanations | ASRS 2023
Various hypotheses have been proposed. Mechanical pressure from the silicone oil may result in ischemia, said Lihteh Wu, M,.D., at the American Society of Retinal Specialists.
What to Expect at the Retinal Specialists Meeting | ASRS 2023
Results from the PULSAR study of high-dose Eylea are scheduled to be presented Saturday morning at the American Society of Retinal Specialists annual scientific meeting, which is being held in Seattle this weekend.
Re Syfovre: ‘It’s a Healthy Debate. It’s a Debate We Should Be Having’ | Charles Wykoff, M.D., Ph.D.
Pros and cons of Syfovre (pegcetacoplan), the newly approved drug for geographic atrophy will be discussed at the American Society of Retinal Specialists annual scientific meeting in Seattle this weekend, predicts leading member of the society. Biosimilars are also on the agenda.
4 Highlights of the ASRS Annual Scientific meeting | Charles Wykoff, M.D., Ph.D.
Charles Wykoff, M.D., Ph.D., director of clinical research at Retina Consultants of Texas, noted new treatments for geographic atrophy are predicted to be a hot topic at the American Society of Retina Specialists annual scientific meeting that starts today in Seattle.
Expanding Optometrist Scope of Practice Did Not Reduce Travel Times
Findings reported in JAMA Ophthalmology chip away at one of the reasons for expanding optometrist scope of practice to include office-based laser procedures. But travel time is not the whole story.
Hepatitis B Vaccination Efforts in Africa Are Flagging
Vaccinations at birth are particularly low, according to a report in Morbidity and Mortality Weekly Report. Models suggest that more than 500,000 hepatitis B-related deaths would be averted if some key vaccination goals were met.
Johns Hopkins Tweaks Name of Health Insurance Plans To Reflect Large, Varied Roles
In addition to a health plan for employees, Johns Hopkins Health Plans has a Medicare Advantage plan, a Medicaid managed care plan and a plan for the families of people who are on active duty in the U.S. military.
D’Andrea Takes the Reins at Catalyst for Payment Reform
MA, Traditional Medicare Differences in Inpatient Rehabilitation Narrowed During the Pandemic
Researchers at the University of Wisconsin also found that the length of stays in inpatient rehabilitation facilities decreased during the 2020 pandemic months relative to 2019 but that payments per episode increased.
Spending on Home Healthcare Projected to Grow Faster Than Other Category, Say CMS Actuaries
In their annual projections of healthcare spending, the actuaries foresee spending on home healthcare growing at annual rate of 7.7% from 2025 to 2031, which is faster than annual growth of 5.6% for health expenditures overall.
FDA Approves First OTC Oral Contraceptive
CVS has said it will sell the OTC oral contraceptive, but news reports today said it probably won't be available in the U.S. till early next year.
7 Things To Know About Hepatitis D
It is dependent on the hepatitis B virus, so as vaccination against hepatitis B has increased, the prevalence of hepatitis D has decreased. A new treatment drug, Gilead's Hepcludex (bulevirtide), has been approved by European drug regulators but not by the FDA.
Express Scripts Adds Cyltezo, Hyrimoz and an Unbranded Version of Hyrimoz to Its Main Formulary
Amgen’s Amjevita was already on the pharmacy benefit manager’s National Preferred Flex Formulary.
Paxlovid Shows No Benefit in Younger, Vaccinated, Healthy Adults, Study Finds
Results reported in the journal Clinical Infectious Diseases did show protection against serious outcomes (emergency room visits, hospitalizations,death) among adults,18-50, with cancer and cardiovascular diseases but no such benefit among those without those diseases. The study also showed no Paxlovid benefit among those with asthma and chronic obstructive pulmonary disorder.
FDA Gives Alzheimer’s Drug Leqembi Full Approval. That Means Medicare Coverage But...
Medicare-eligible patients need to be enrolled in registry to get Medicare coverage for the anti-beta amyloid drug that is priced to cost $26,500 a year.
8 Humira Biosimilars Are on the Market
7 of them launched during the first several days of July, joining Amgen's Amjevita in the suddenly crowded market of Humira competitors. Pfizer’s Abrilada is the only FDA-approved Humira biosimilar that hasn’t launched.
Cyltezo, First Interchangeable Humira Biosimilar, Hits the Market
Boehringer Ingelheim is pricing its biosimilar 5% to 7% below AbbVie’s top selling drug.
Care After Hospitalization for Traumatic Brain Injury
Researchers found that 80% of patients were living in the community 90 days after discharge.
Bringing Algorithms to Post-Acute Care: Russell Graney and Aidin
Russell Graney, founder and CEO of Aidin, believes that his company can transform post-acute care and its referral process far more efficient.
FDA approves Roctavian, the First Gene Therapy for Hemophilia A
The price tag of $2.9 million is typical of a new wave of gene therapies. The manufacturer, BioMarin Pharmaceutical, is offering arrangements that will link the price paid by payers to how well patients respond to the treatment.
Pearson Stepping Down as Head of ICER, Emond Taking Over
Sarah K. Emond, M.P.P., will take over as president and CEO of the Institute for Clinical and Economic Review (ICER) next year. Steve Pearson, M.D.,M.Sc., founded the organization, which has become the leading cost-effectiveness assessment organization of pharmaceuticals in the U.S.
2 Clarke Drive Cranbury, NJ 08512